Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Powerful mechanism helps viruses evade body's immune response

Researchers at the Salk Institute for Biological Studies have discovered a powerful mechanism by which viruses such as influenza, West Nile and Dengue evade the body's immune response and infect humans with these potentially deadly diseases. The findings may provide scientists with an attractive target for novel antiviral therapies.

19 Aug 2013

Study: Gene that controls ageing process linked to cancer

A gene that helps control the ageing process by acting as a cell's internal clock has been linked to cancer by a major new study.

19 Aug 2013

DLBCLs resistant to chemotherapy can be reprogrammed to respond using azacitidine

A phase I clinical trial showed diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy can be reprogrammed to respond to treatment using the drug azacitidine, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

17 Aug 2013

ASH announces 12 recipients of its second round of ASH Bridge Grants

As federal funding cuts continue to jeopardize the progress of biomedical research, the American Society of Hematology (ASH), the world's largest professional organization dedicated to the causes and treatments of blood disorders, today announced the 12 recipients of its second round of ASH Bridge Grants.

16 Aug 2013

Study reveals cancer in humans linked with high amounts of proteins responsible for cells division

Cancer in humans is frequently associated with unusually high amounts of one or more proteins responsible for controlling the rate at which cells divide. As an example, excessive amounts of the cyclin-dependent kinase CDK6 are often found in types of cancer such as lymphoma.

14 Aug 2013

Study reports high survival rates for children with rare subtype of leukaemia

A pioneering genetic study means that children with a rare subtype of leukaemia have 75% less chance of their leukaemia recurring.

13 Aug 2013

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes.

13 Aug 2013

Research suggests blocking DNA repair complex helps fight therapy-resistant leukemia

New research posted online by the Nature journal Leukemia suggests blocking part of a DNA repair complex that helps some types of leukemia resist treatment can increase the effectiveness of chemotherapy and enhance survival.

9 Aug 2013

Study: Immune-regulating molecules can trigger lymphomas

A small group of immune-regulating molecules, when overproduced even moderately, can trigger the blood cancers known as lymphomas, according to a new study led by scientists from The Scripps Research Institute (TSRI).

9 Aug 2013

Journey Forward creates tool to help cancer survivors initiate care planning with health care providers

Journey Forward, a leader in Survivorship Care Planning, is moving forward patient-centered care by enhancing its suite of free, award-winning survivorship care planning tools with My Care Plan.

9 Aug 2013

Eisai's investigational compound receives orphan drug designation for cutaneous t-cell lymphoma

Eisai Inc. announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its investigational compound (E7777) for cutaneous t-cell lymphoma. E7777 is designed to have an improved purity profile and manufacturing process.

9 Aug 2013

High mobility group (HMG) genes and cancer: an interview with Dr. Linda Resar, Johns Hopkins University School of Medicine

High mobility group A genes are highly expressed in all aggressive cancers studied to date. These genes encode the high mobility group A (HMGA) proteins. In other words, these genes provide the genetic “code” necessary to produce HMGA proteins.

8 Aug 2013

Brain tumor cells in arrested development contribute to cell variety that protects cancer

A program that pushes immature cells to grow up and fulfill their destiny as useful, dedicated cells is short-circuited in the most common and deadly form of brain tumor, scientists at The University of Texas MD Anderson Cancer Center report this week in the Early Edition of the Proceedings of the National Academy of Sciences.

8 Aug 2013

Autologous tumor cell vaccination: An effective strategy to advance long-term leukemia control

Patients with advanced chronic lymphocytic leukemia often receive donor transplants that effectively "reboot" their own immune defenses, which then attack and potentially cure the hard-to-treat disease. However, there is a high rate of relapse in these patients, and the transplanted immune cells may also harm normal tissues, causing graft-versus-host disease.

7 Aug 2013

Tumor cell vaccination has potential to enhance anti-tumor responses following allo-HSCT

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that most often affects older adults. CLL responds to bone marrow stem cell transplantation (allo-HSCT); however, the rate of relapse for CLL remains relatively high.

6 Aug 2013

Celiac disease patients with persistent intestine damage are at higher risk of lymphoma

Patients with celiac disease who had persistent intestine damage (identified with repeat biopsy) had a higher risk of lymphoma than patients whose intestines healed, according to findings published in the August 6, 2013, issue of Annals of Internal Medicine.

6 Aug 2013

Columbia researchers identify 18 new genes that drive glioblastoma multiforme

A team of researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center has identified 18 new genes responsible for driving glioblastoma multiforme, the most common-and most aggressive-form of brain cancer in adults. The study was published August 5, 2013, in Nature Genetics.

6 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

Researchers identify precise method for determining bone marrow involvement in DLBCL patients

A more precise method for determining bone marrow involvement in patients with diffuse large B-cell lymphoma-a key factor in tailoring patient management plans-has been identified by researchers in a study published in the August issue of The Journal of Nuclear Medicine.

2 Aug 2013

Lymphoma News and Research

Further Reading

Powerful mechanism helps viruses evade body's immune response

Study: Gene that controls ageing process linked to cancer

DLBCLs resistant to chemotherapy can be reprogrammed to respond using azacitidine

ASH announces 12 recipients of its second round of ASH Bridge Grants

Study reveals cancer in humans linked with high amounts of proteins responsible for cells division

Study reports high survival rates for children with rare subtype of leukaemia

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

Research suggests blocking DNA repair complex helps fight therapy-resistant leukemia

Study: Immune-regulating molecules can trigger lymphomas

Journey Forward creates tool to help cancer survivors initiate care planning with health care providers

Eisai's investigational compound receives orphan drug designation for cutaneous t-cell lymphoma

High mobility group (HMG) genes and cancer: an interview with Dr. Linda Resar, Johns Hopkins University School of Medicine

Brain tumor cells in arrested development contribute to cell variety that protects cancer

Autologous tumor cell vaccination: An effective strategy to advance long-term leukemia control

Tumor cell vaccination has potential to enhance anti-tumor responses following allo-HSCT

Celiac disease patients with persistent intestine damage are at higher risk of lymphoma

Columbia researchers identify 18 new genes that drive glioblastoma multiforme

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

ImmunoGen reports net loss of $21.9 million in Q4 2013

Researchers identify precise method for determining bone marrow involvement in DLBCL patients

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News